Paxil Failure-To-Warn Claims are Not Preempted, Judge Rules
December 30, 2009
DOCUMENTS
- Opinion and Order
OKLAHOMA CITY - Federal law does not preempt failure-to-warn claims brought against the manufacturer of Paxil because the drug maker provided no evidence that it tried to strengthen the label's warnings regarding pregnancy-related risks prior to September 2005, an Oklahoma federal judge has ruled. Hayes, et ux. v. GlaxoSmithKline, No. 07-0682 (N.D. Okla.).
On Dec. 14, Chief Judge Claire V. Eagan of the U.S. District Court for the Northern District of Oklahoma also denied GlaxoSmithKline's motion for summary judgment on plaintiffs' punitive damage claims, ruling that a jury could find that GSK "acted recklessly or with conscious disregard for the …
UPCOMING CONFERENCES

HarrisMartin's New Jersey Asbestos Litigation Conference
March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick

HarrisMartin's Webinar Series: Suboxone (Buprenorphine/Naloxone) Film Marketing, Sales Practices and Products Litigation - MDL No. 3092
December 18, 2023